{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T18:43:48Z","timestamp":1786387428774,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T00:00:00Z","timestamp":1703030400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100006752","name":"Universidade do Porto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100006752","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1007\/s40265-023-01988-0","type":"journal-article","created":{"date-parts":[[2023,12,20]],"date-time":"2023-12-20T03:02:22Z","timestamp":1703041342000},"page":"45-58","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Spesolimab for the Treatment of Generalized Pustular Psoriasis"],"prefix":"10.1007","volume":"84","author":[{"given":"Diana","family":"Bernardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0404-0870","authenticated-orcid":false,"given":"Tiago","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,20]]},"reference":[{"issue":"Suppl 1","key":"1988_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s40257-021-00655-y","volume":"23","author":"S Marrakchi","year":"2022","unstructured":"Marrakchi S, Puig L. Pathophysiology of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):13\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"2 Suppl","key":"1988_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.12788\/cutis.0579","volume":"110","author":"KA Reynolds","year":"2022","unstructured":"Reynolds KA, Pithadia DJ, Lee EB, et al. Generalized pustular psoriasis: a review of the pathophysiology, clinical manifestations, diagnosis, and treatment. Cutis. 2022;110(2 Suppl):19\u201325.","journal-title":"Cutis"},{"issue":"11","key":"1988_CR3","doi-asserted-by":"publisher","first-page":"1792","DOI":"10.1111\/jdv.14386","volume":"31","author":"AA Navarini","year":"2017","unstructured":"Navarini AA, Burden AD, Capon F, et al. ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. J Eur Acad Dermatol Venereol. 2017;31(11):1792\u20139.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"Suppl 1","key":"1988_CR4","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s40257-021-00654-z","volume":"23","author":"SE Choon","year":"2022","unstructured":"Choon SE, Navarini AA, Pinter A. Clinical course and characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):21\u20139.","journal-title":"Am J Clin Dermatol"},{"issue":"26","key":"1988_CR5","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"issue":"3","key":"1988_CR6","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s13555-022-00881-0","volume":"13","author":"R Rivera-D\u00edaz","year":"2023","unstructured":"Rivera-D\u00edaz R, Daud\u00e9n E, Carrascosa JM, Cueva P, Puig L. Generalized pustular psoriasis: a review on clinical characteristics, diagnosis, and treatment. Dermatol Ther (Heidelb). 2023;13(3):673\u201388.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"2","key":"1988_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/1346-8138.16609","volume":"50","author":"A Morita","year":"2023","unstructured":"Morita A, Tsai TF, Yee EY, et al. Efficacy and safety of spesolimab in Asian patients with a generalized pustular psoriasis flare: results from the randomized, double-blind, placebo-controlled Effisayil\u2122 1 study. J Dermatol. 2023;50(2):183\u201394.","journal-title":"J Dermatol"},{"issue":"Suppl 1","key":"1988_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s40257-021-00664-x","volume":"23","author":"M Zheng","year":"2022","unstructured":"Zheng M, Jullien D, Eyerich K. The prevalence and disease characteristics of generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):5\u201312.","journal-title":"Am J Clin Dermatol"},{"issue":"8","key":"1988_CR9","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/exd.14765","volume":"32","author":"N Kodali","year":"2023","unstructured":"Kodali N, Blanchard I, Kunamneni S, Lebwohl MG. Current management of generalized pustular psoriasis. Exp Dermatol. 2023;32(8):1204\u201318.","journal-title":"Exp Dermatol"},{"key":"1988_CR10","first-page":"37","volume":"9","author":"K Ly","year":"2019","unstructured":"Ly K, Beck KM, Smith MP, Thibodeaux Q, Bhutani T. Diagnosis and screening of patients with generalized pustular psoriasis. Psoriasis (Auckl). 2019;9:37\u201342.","journal-title":"Psoriasis (Auckl)."},{"issue":"6","key":"1988_CR11","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1007\/s13555-021-00612-x","volume":"11","author":"A Menter","year":"2021","unstructured":"Menter A, Van Voorhees AS, Hsu S. Pustular psoriasis: a narrative review of recent developments in pathophysiology and therapeutic options. Dermatol Ther (Heidelb). 2021;11(6):1917\u201329.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"11","key":"1988_CR12","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1111\/1346-8138.14523","volume":"45","author":"H Fujita","year":"2018","unstructured":"Fujita H, Terui T, Hayama KH, et al. Japanese guidelines for the management and treatment of generalized pustular psoriasis: the new pathogenesis and treatment of GPP. J Dermatol. 2018;45(11):1235\u201370.","journal-title":"J Dermatol"},{"issue":"12","key":"1988_CR13","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.3390\/biomedicines9121746","volume":"9","author":"G Genovese","year":"2021","unstructured":"Genovese G, Moltrasio C, Cassano N, Maronese CA, Vena GA, Marzano AV. Pustular psoriasis: from pathophysiology to treatment. Biomedicines. 2021;9(12):1746.","journal-title":"Biomedicines."},{"issue":"Suppl 1","key":"1988_CR14","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40257-021-00658-9","volume":"23","author":"J Krueger","year":"2022","unstructured":"Krueger J, Puig L, Tha\u00e7i D. Treatment options and goals for patients with generalized pustular psoriasis. Am J Clin Dermatol. 2022;23(Suppl 1):51\u201364.","journal-title":"Am J Clin Dermatol"},{"key":"1988_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2022.155897","volume":"156","author":"KL Sachen","year":"2022","unstructured":"Sachen KL, Arnold Greving CN, Towne JE. Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. Cytokine. 2022;156: 155897.","journal-title":"Cytokine"},{"issue":"2","key":"1988_CR16","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1177\/1203475419888862","volume":"24","author":"K Ratnarajah","year":"2020","unstructured":"Ratnarajah K, Jfri A, Litvinov IV, Netchiporouk E. Spesolimab: a novel treatment for pustular psoriasis. J Cutan Med Surg. 2020;24(2):199\u2013200.","journal-title":"J Cutan Med Surg"},{"issue":"10","key":"1988_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMc1811317","volume":"380","author":"H Bachelez","year":"2019","unstructured":"Bachelez H, Choon SE, Marrakchi S, et al. Inhibition of the interleukin-36 pathway for the treatment of generalized pustular psoriasis. N Engl J Med. 2019;380(10):981\u20133.","journal-title":"N Engl J Med"},{"key":"1988_CR18","doi-asserted-by":"crossref","unstructured":"Blair HA. Spesolimab: first approval. Drugs. 2022;82(17):1681\u20131686 (Erratum in: Drugs. 2023 Jan;83(1):103).","DOI":"10.1007\/s40265-022-01801-4"},{"issue":"11","key":"1988_CR19","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2023.2265295","volume":"22","author":"L Potestio","year":"2023","unstructured":"Potestio L, Camela E, Cacciapuoti S, et al. Efficacy and safety of spesolimab for the management of generalized pustular psoriasis: a drug safety evaluation. Expert Opin Drug Saf. 2023;22(11):1003\u201310.","journal-title":"Expert Opin Drug Saf"},{"issue":"16","key":"1988_CR20","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.2147\/CCID.S407812","volume":"28","author":"M Megna","year":"2023","unstructured":"Megna M, Camela E, Ruggiero A, et al. Use of biological therapies for the management of pustular psoriasis: a new era? Clin Cosmet Investig Dermatol. 2023;28(16):1677\u201390.","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"3","key":"1988_CR21","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/1346-8138.15196","volume":"47","author":"H Saeki","year":"2020","unstructured":"Saeki H, Terui T, Morita A, et al. Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol. 2020;47(3):201\u201322.","journal-title":"J Dermatol"},{"issue":"3","key":"1988_CR22","doi-asserted-by":"publisher","first-page":"adv00034","DOI":"10.2340\/00015555-3388","volume":"100","author":"H Bachelez","year":"2020","unstructured":"Bachelez H. Pustular psoriasis: the dawn of a new era. Acta Derm Venereol. 2020;100(3):adv00034.","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"1988_CR23","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1080\/1744666X.2019.1648209","volume":"15","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Van Voorhees AS, Lebwohl MG. An update on generalized pustular psoriasis. Expert Rev Clin Immunol. 2019;15(9):907\u201319.","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"1988_CR24","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/bjd.12548","volume":"170","author":"U H\u00fcffmeier","year":"2014","unstructured":"H\u00fcffmeier U, W\u00e4tzold M, Mohr J, Sch\u00f6n MP, M\u00f6ssner R. Successful therapy with anakinra in a patient with generalized pustular psoriasis carrying IL36RN mutations. Br J Dermatol. 2014;170(1):202\u20134.","journal-title":"Br J Dermatol"},{"issue":"1","key":"1988_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjd.14685","volume":"176","author":"P Skendros","year":"2017","unstructured":"Skendros P, Papagoras C, Lefaki I, et al. Successful response in a case of severe pustular psoriasis after interleukin-1\u03b2 inhibition. Br J Dermatol. 2017;176(1):212\u20135.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1988_CR26","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1093\/bjd\/ljad083","volume":"189","author":"RB Warren","year":"2023","unstructured":"Warren RB, Reich A, Kaszuba A, et al. Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial. Br J Dermatol. 2023;189(2):161\u20139.","journal-title":"Br J Dermatol"},{"issue":"6","key":"1988_CR27","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.jaci.2017.05.019","volume":"140","author":"M Akiyama","year":"2017","unstructured":"Akiyama M, Takeichi T, McGrath JA, Sugiura K. Autoinflammatory keratinization diseases. J Allergy Clin Immunol. 2017;140(6):1545\u20137.","journal-title":"J Allergy Clin Immunol"},{"issue":"16","key":"1988_CR28","doi-asserted-by":"publisher","first-page":"9479","DOI":"10.3390\/ijms23169479","volume":"23","author":"H Iznardo","year":"2022","unstructured":"Iznardo H, Puig L. IL-1 family cytokines in inflammatory dermatoses: pathogenetic role and potential therapeutic implications. Int J Mol Sci. 2022;23(16):9479.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"1988_CR29","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1007\/s40259-023-00587-5","volume":"37","author":"R Fukaura","year":"2023","unstructured":"Fukaura R, Akiyama M. Targeting IL-36 in inflammatory skin diseases. BioDrugs. 2023;37(3):279\u201393.","journal-title":"BioDrugs"},{"key":"1988_CR30","doi-asserted-by":"crossref","unstructured":"Mahil SK, Catapano M, Di Meglio P, et al. An analysis of IL-36 signature genes and individuals with IL1RL2 knockout mutations validates IL-36 as a psoriasis therapeutic target [published erratum appears in: Sci Transl Med. 2017 Dec;9(420):eaar6600]. Sci Transl Med. 2017;9(411):eaan2514.","DOI":"10.1126\/scitranslmed.aan2514"},{"issue":"1","key":"1988_CR31","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"1988_CR32","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","volume":"149","author":"P Baum","year":"2022","unstructured":"Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402\u201312.","journal-title":"J Allergy Clin Immunol"},{"issue":"11","key":"1988_CR33","doi-asserted-by":"publisher","first-page":"2514","DOI":"10.1038\/jid.2013.230","volume":"133","author":"K Sugiura","year":"2013","unstructured":"Sugiura K, Takemoto A, Yamaguchi M, et al. The majority of generalized pustular psoriasis without psoriasis vulgaris is caused by deficiency of interleukin-36 receptor antagonist. J Invest Dermatol. 2013;133(11):2514\u201321.","journal-title":"J Invest Dermatol"},{"issue":"6","key":"1988_CR34","doi-asserted-by":"publisher","first-page":"118","DOI":"10.3892\/ijmm.2021.4951","volume":"47","author":"J Zhou","year":"2021","unstructured":"Zhou J, Luo Q, Cheng Y, Wen X, Liu J. An update on genetic basis of generalized pustular psoriasis (review). Int J Mol Med. 2021;47(6):118.","journal-title":"Int J Mol Med"},{"key":"1988_CR35","unstructured":"US FDA. SPEVIGO\u00ae (spesolimab-sbzo) injection, for intravenous use: highlights of prescribing information. 2022 Sep; Reference ID: 5039554. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761244s000lbl.pdf. Accessed 22 Oct 2023."},{"issue":"3","key":"1988_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-043666","volume":"11","author":"SE Choon","year":"2021","unstructured":"Choon SE, Lebwohl MG, Marrakchi S, et al. Study protocol of the global Effisayil 1 Phase II, multicentre, randomised, double-blind, placebo-controlled trial of spesolimab in patients with generalized pustular psoriasis presenting with an acute flare. BMJ Open. 2021;11(3): e043666.","journal-title":"BMJ Open"},{"issue":"4","key":"1988_CR37","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1111\/jdv.18820","volume":"37","author":"AA Navarini","year":"2023","unstructured":"Navarini AA, Prinz JC, Morita A, et al. Spesolimab improves patient-reported outcomes in patients with generalized pustular psoriasis: results from the Effisayil 1 study. J Eur Acad Dermatol Venereol. 2023;37(4):730\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"1988_CR38","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1111\/exd.14824","volume":"32","author":"AD Burden","year":"2023","unstructured":"Burden AD, Okubo Y, Zheng M, et al. Efficacy of spesolimab for the treatment of generalized pustular psoriasis flares across pre-specified patient subgroups in the Effisayil 1 study. Exp Dermatol. 2023;32(8):1279\u201383.","journal-title":"Exp Dermatol"},{"issue":"1","key":"1988_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s13555-022-00835-6","volume":"13","author":"A Morita","year":"2023","unstructured":"Morita A, Choon SE, Bachelez H, et al. Design of Effisayil\u2122 2: a randomized, double-blind, placebo-controlled study of spesolimab in preventing flares in patients with generalized pustular psoriasis. Dermatol Ther (Heidelb). 2023;13(1):347\u201359.","journal-title":"Dermatol Ther (Heidelb)."},{"issue":"10412","key":"1988_CR40","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"key":"1988_CR41","unstructured":"ClinicalTrials.gov. EffisayilTM ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT03886246. Accessed 22 Oct 2023."},{"key":"1988_CR42","unstructured":"ClinicalTrials.gov. An expanded access trial in Japan to provide spesolimab to people with a flare-up in generalized pustular psoriasis who have no other treatment options. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05200247. Accessed 22 Oct 2023."},{"key":"1988_CR43","unstructured":"ClinicalTrials.gov. An expanded access program in china to provide spesolimab to people with a flare-up in generalized pustular psoriasis who have no other treatment options. https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT05239039. Accessed 22 Oct 2023."},{"key":"1988_CR44","unstructured":"Xiujiang Li, et al. Characterisation of the immunogenicity of spesolimab in patients with a generalized pustular psoriasis (GPP) flare [abstract no. P094]. Presented at the 51st European Society for Dermatological Research Annual Meeting: Sep 2022; Amsterdam."},{"key":"1988_CR45","unstructured":"ClinicalTrials.gov. An open-label, multicenter, single-arm, post-marketing trial to evaluate efficacy and safety and the impact of immunogenicity on efficacy, safety, and pharmacokinetics of spesolimab I.V. in treatment of patients with generalized pustular psoriasis presenting with a recurrent flare following their initial GPP flare treatment with spesolimab I.V. https:\/\/clinicaltrials.gov\/study\/NCT06013969?cond=Generalized%20Pustular%20Psoriasis&intr=spesolimab&aggFilters=status:not%20rec&rank=1\u201d. Accessed 22 Oct 2023."},{"issue":"2","key":"1988_CR46","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","volume":"11","author":"U Mrowietz","year":"2021","unstructured":"Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11(2):571\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"2","key":"1988_CR47","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14740338.2022.2103536","volume":"22","author":"M Ferrante","year":"2023","unstructured":"Ferrante M, Irving PM, Selinger CP, et al. Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opin Drug Saf. 2023;22(2):141\u201352.","journal-title":"Expert Opin Drug Saf"},{"issue":"10","key":"1988_CR48","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s13555-023-01002-1","volume":"13","author":"AD Burden","year":"2023","unstructured":"Burden AD, Bissonnette R, Navarini AA, et al. Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study. Dermatol Ther (Heidelb). 2023;13(10):2279\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1988_CR49","unstructured":"ClinicalTrials.gov. Post-marketing surveillance of spesolimab I.V. infusion in improvement of generalized pustular psoriasis with acute symptoms in Japan. https:\/\/clinicaltrials.gov\/study\/NCT05670821?term=NCT05670821&rank=1. Accessed 22 Oct 2023."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-023-01988-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-023-01988-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,16]],"date-time":"2024-01-16T03:12:59Z","timestamp":1705374779000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-023-01988-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,20]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["1988"],"URL":"https:\/\/doi.org\/10.1007\/s40265-023-01988-0","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,20]]},"assertion":[{"value":"3 December 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Open access funding provided by FCT|FCCN (b-on).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Diana Bernado has no conflicts of interest to declare in relation to this work. Diamant Tha\u00e7i has received honoraria for participation on advisory boards, as a speaker, and for consultancy services from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, Galderma, Janssen, LEO Pharma, Novartis, Pfizer, Regeneron, Sanofi Genzyme, and UCB Pharma; and has received research grants from LEO Pharma and Novartis. Tiago Torres has received consultancy and\/or speaker\u2019s honoraria from, and\/or participated in clinical trials sponsored by, AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Biocad, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Fresenius-Kabi, Janssen, LEO Pharma, Eli Lilly, MSD, Mylan, Novartis, Pfizer, Samsung-Bioepis, Sanofi-Genzyme, Sandoz and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"DB, DT, and TT conceived the idea for this article, performed the literature search and data analysis, and drafted and critically revised the work.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}